ARGNF News and Press, Argen X NV From 06/29/23

2023-06-29 21:55:49 ET Summary argenx has received approval for the subcutaneous version of efgartigimod, a drug for treating myasthenia gravis, but the market did not respond positively to the news, and the company's share price remained relatively stable. The drug's label did no...

VYVGART ® Hytrulo is first FDA - approved subcutaneous (SC) inject able for generalized myasthenia gravis ( gMG ) With this approval, argenx broadens innovative gMG product offering and demonstrates continued...

Independent Data Monitoring Committee recommend ed study continuation based on the favorable safety profile observed in the first dose cohort Early efficacy signals support proof-of-concept of empasiprubart in multifo...

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...

2023-05-10 04:56:00 ET Summary Baron Fifth Avenue Growth Fund gained 19.7% during the first quarter, which compares to gains of 14.4% for the Russell 1000 Growth Index and 7.5% for the S&P 500 Index, the Fund’s benchmarks. The Fund is constructed on a bottom-up basis wi...

2023-05-06 17:57:09 ET argenx SE (ARGX) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz -...

2023-05-04 04:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 3.75% (Institutional Shares) during the first q...

$218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART received marketing authorization in Israel through partnership with Medison 88 events achieved in ADHERE trial; topline data now expected in July 2023 Enrollment completed...

May 3 , 2023 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders he...

2023-05-02 17:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund® climbed 17.96% (Institutional S...